An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Clinical trial NCT03147742 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT03147742
- Sponsor
- Incyte Corporation
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.